Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|January 2, 2019
- Pharmaceutical Technology-01-02-2019
- Volume 43
- Issue 1
Improved Mixer Lift and Seal Designs
Charles Ross & Son Company has made improvements to the dual-post hydraulic lift and seal design of its 1500-gallon Multi-Shaft Mixer Model PVM-1500.
Charles Ross & Son Company has made improvements to the dual-post hydraulic lift and seal design of its 1500-gallon Multi-Shaft Mixer Model PVM-1500. The new lifting design is a double-acting, fully hydraulic cylinder operating at a higher pressure, allowing for a smaller cylinder and less oil for operation. David Hathaway, vice-president of Ross Engineering, states that with the new design, the lifting system provides faster lifting speed when raising and lowering the agitators.
The new seal arrangement allows seal replacement without removing agitator shafts. Unlike the historical design, seal replacement no longer requires removal of the mixer from the tank nor tank entry to access the seal.
The PVM-1500 features three independently driven agitators: a screw auger, a high-speed disperser, and a three-wing anchor agitator. The sides and bottom of the changeable mixing vessel are insulated and jacketed for up to 50 psig. According to the company, this vacuum-rated machine can run continuously and is supplied with rugged touchscreen controls showing digital readouts for speed, cycle time, vacuum level, and batch temperature.
Articles in this issue
over 7 years ago
Packaging Peril: ‘No-Deal’ Brexit May Lead to Missed Deadlineover 7 years ago
Looking Beyond the Deadlineover 7 years ago
Great Expectationsalmost 8 years ago
Smarter Packaging Comes to the Pharma Marketalmost 8 years ago
Continuous Processing: Challenges and Opportunities of Virus Filtrationalmost 8 years ago
Tabletop Spray Dryeralmost 8 years ago
Microplate Spectrophotometeralmost 8 years ago
Electrical Position Indicator for Linear Actuatorsalmost 8 years ago
FDA Marks Record Year for New Drug Approvalsalmost 8 years ago
Internal and External Challenges to Pharma in 2019Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.